New vaccine booster aims to shield against multiple coronaviruses

NCT ID NCT07113106

First seen Apr 15, 2026 · Last updated Jun 14, 2026 · Updated 7 times

Summary

This early-stage trial tests a new booster vaccine, CD40.Pan.CoV, designed to protect against several types of coronaviruses. About 48 healthy adults in France will receive either a low or high dose, with or without an adjuvant (a substance that boosts immune response). The main goals are to check the vaccine's safety and measure the antibodies it produces.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CIC 1403 CHU de Lille

    Lille, 59037, France

  • CIC 1405 CHU Clermont Ferrand

    Clermont-Ferrand, 63000, France

  • CIC 1413 CHU de Nantes

    Nantes, 44093, France

  • CIC 1417 Cochin-Pasteur Hôpital Cochin

    Paris, 75014, France

  • CIC 1427 Hôpital St Louis

    Paris, 75475, France

  • Centre de Recherche Clinique CHU de Caen Normandie

    Caen, 14033, France

  • Hôpital Henri Mondor

    Créteil, 94010, France

Conditions

Explore the condition pages connected to this study.